Karyopharm

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Morgan Prestwich were retained to appoint the following positions in the US:
- SVP Global Head of Quality
- Senior Director Commercial Innovation
- Executive Pharmacovigilance Medical Director
- Director Quality